《大行報告》花旗:中海油(00883.HK)上季盈利符預期 派息有望提升
花旗發表報告指,中海油(00883.HK)發盈喜,預料去年盈利介乎1,400億元至1,440億元人民幣,意味去年第四季利潤約300億元至350億元人民幣,符合該行預期。
該行認為,雖然布蘭特油價於去第四季按季由97美元下跌至88美元,但由於較預期佳的成本控制和產量增長,中海油成功保持與第三季相當的利潤,集團亦承諾派發不少於40%的股息(或最低每股0.7港元)。
因現金流強勁及盈利能力創紀錄,花旗料中海油於3月公布的股息有潛在上升空間,或於短期內為股價提供支持,維持其股份「買入」評級及目標價17元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.